IN8bio (INAB)

• Market cap: $14.8M
• 1 day: -1.74%
• 5 days: -4.52%
• 1 month: 1.81%
• 3 months: -31.83%
• 6 months: -37.43%
• Year to date: -39.69%
• 1 year: -83.43%
• 5 years: -98.31%
• 10 years: -98.31%
• Sector: Healthcare
• Industry: Biotechnology

About: IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Employees: 18

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

275% more capital invested

Capital invested by funds: $2.06M [Q3] → $7.72M (+$5.66M) [Q4]

120% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 5

25.13% more ownership

Funds ownership: 16.3% [Q3] → 41.43% (+25.13%) [Q4]

0% more funds holding

Funds holding: 26 [Q3] → 26 (+0) [Q4]

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1.20 610% upside
• Avg. target: $3.60 2,030% upside
• High target: $6 3,450% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 57 / 190 met price target	3,450% upside $6	Buy Maintained	14 Mar 2025
Jones Trading Soumit Roy 15% 1-year accuracy 2 / 13 met price target	610% upside $1.20	Buy Upgraded	11 Feb 2025